| Name | Title | Contact Details |
|---|
Diagenics is a Woburn, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Geneos is developing personalized immunotherapies against tumor specific neoantigens which arise from gene mutations in cancerous cells.
OncoResponse Inc., a privately held immuno-oncology company, has partnered with MD Anderson Cancer Center (MDACC) to deploy a unique and transformational approach to the discovery of cancer therapeutics.
The focus of Regen BioPharma, Inc. is to developing translational medicine platforms for the rapid commercialization of stem cell therapies and to advance intellectual property licensed from entities, institutions and universities that show promise towards fulfilling the purpose of increased quality of life. Regen BioPharma has reviewed more than 20,000 US issued patents covering stem cell related subject matter, created a shortlist of 30 promising technologies for rapid commercialization, and currently is in negotiations to license several of these. The Regen BioPharma business model is to take multiple stem cell therapeutics to and through the human "safety and signal of efficacy" stage (Phase I/II clinical trials), followed by exit. Having assembled a core infrastructure specialized in obtaining regulatory approval and executing clinical trials in cell therapy, we aim to act as a "superincubator" that within 1-2 years grows technologies from laboratory to an asset ready for spin-off or sale.
ACT Services is a Saint Paul, MN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.